You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

NEW YORK, Jan. 11, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced todaythat its Chairman & CEO, Sam Salman, will be virtually presenting at the 39th Annual J.P. Morgan Healthcare Conference.Mr. Salman will introduce miR Scientific's proprietary, highly accurate, award winning sncRNA interrogation platform, highlight its recentFDA breakthrough designationand present miR's commercial launch plans for itsnon-invasive liquid biopsy urine test. Mr. Salman will also introduce clinical collaboration roadmaps, the company's product pipeline and global growth initiatives. The presentation is scheduled for Wednesday, January 13th, 2021 and will begin at 3:10pm EDT. A live webcast for conference participants will be availablehere. About miR Scientific miR Scientific, LLC, is a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease. Our team developed the miR Scientific Disease Management Platform, which is comprised of proprietary, non-invasive and highly accurate liquid biopsy urine tests for the detection, classification and monitoring of urological cancers.The Platform is being utilized to commercialize its award-winning miR Sentinel Prostate Test. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered inNew YorkCity with operating subsidiaries inIsrael,CanadaandPuerto Rico. Media Contact: Karen Sharma+1 (781) 235-3060[emailprotected] SOURCE miR Scientific, LLC

Answer: miR Scientific to Present the Prostate Cancer Application of its Liquid Biopsy Disease Management Platform at the 39th Annual J.P. Morgan Healthcare Conference First-of-its-kind, high-throughput and validated sncRNA interrogation platform that provides highly accurate molecular measure of malignancy for detection, risk classification and monitoring of tumors from a single urine specimen without the need for invasive biopsies